Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 47.64M P/E - EPS this Y 168.60% Ern Qtrly Grth -
Income 19.84M Forward P/E -1.05 EPS next Y -278.40% 50D Avg Chg -
Sales 72.65M PEG -10.00 EPS past 5Y - 200D Avg Chg 16.00%
Dividend N/A Price/Book 1.39 EPS next 5Y -0.10% 52W High Chg -38.00%
Recommedations 2.30 Quick Ratio 7.40 Shares Outstanding 6.66M 52W Low Chg 79.00%
Insider Own 0.54% ROA 8.30% Shares Float 4.94M Beta 0.64
Inst Own 47.58% ROE 36.80% Shares Shorted/Prior 7.83K/12.48K Price 7.15
Gross Margin 135.73% Profit Margin 27.32% Avg. Volume 58,862 Target Price 23.00
Oper. Margin 20.67% Earnings Date May 9 Volume 17,020 Change -3.90%
About MEI Pharma, Inc.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEI Pharma, Inc. News
04/11/24 MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
04/11/24 MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
04/10/24 MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
03/26/24 MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
03/09/24 12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
02/13/24 MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
02/13/24 MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
02/08/24 Is MEI Pharma (MEIP) Attractively Priced?
01/16/24 MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
12/11/23 MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
11/27/23 11 Cheapest Stocks With Biggest Upside
11/17/23 AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
11/10/23 Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
11/09/23 MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
11/09/23 Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated
11/08/23 MEI Pharma to Present at the Stifel 2023 Healthcare Conference
11/07/23 Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
11/06/23 MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
11/02/23 Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View
11/02/23 MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
MEIP Chatroom

User Image Trendrebel Posted - 3 days ago

$MEIP Wow, it´s weak ! Has never been cheaper. 20M, and the company is yours. As a premium you´ll have 50M :-)

User Image RipVanWinkleman Posted - 3 days ago

$MEIP http://stocktwits.com/RipVanWinkleman/message/569550779

User Image andrave Posted - 6 days ago

$MEIP piece of sh*t ...

User Image DonCorleone77 Posted - 1 week ago

$MEIP 2 of 2 - MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC ....framework to advance both clinical programs in a manner intended to address significant medical needs while prioritizing a measured and objective-based allocation of our resources," said David Urso, president and chief executive officer of MEI Pharma..."The entire MEI Board is pleased to unanimously align around a strategy that we believe is in the best interests of the Company's shareholders, with the intent to optimize the opportunity to judiciously advance both of the voruciclib and ME-344 development programs," stated Taheer Datoo, director of MEI Pharma and principal and portfolio manager of Anson Funds. "Under the strategy, use of capital is measured and balanced to achieve key clinical objectives designed to optimize the development potential these product candidates hold to advance the standard of care for patients with cancer while also optimizing the interests of our shareholders."

User Image DonCorleone77 Posted - 1 week ago

$MEIP 1 of 2 - MEI Pharma prioritizes voruciclib, will not continue with 2nd ROC MEI Pharma reported that the company's Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionally, the Company's Board of Directors unanimously determined not to proceed with a second return of capital under the October 31 Anson Funds and Cable Car Capital cooperation agreement in order to conserve resources and align strategic investment, and thereby extend the Company's operational runway. "We are very fortunate as a development-stage therapeutics company to have two very promising oncology candidates, voruciclib and ME-344, that continue to generate data supporting their potential as novel therapeutics to benefit patients with cancer. With the MEI Board aligned around our strategy, we have a productive...

User Image Trendrebel Posted - 1 week ago

$MEIP Brilliant news. Lets see a positive reaction from the market

User Image Stock_Titan Posted - 1 week ago

$MEIP MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients https://www.stocktitan.net/news/MEIP/mei-pharma-reports-initial-data-from-clinical-study-evaluating-me-iviqliwl54se.html

User Image Stock_Titan Posted - 1 week ago

$MEIP MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum https://www.stocktitan.net/news/MEIP/mei-pharma-to-present-at-the-stifel-2024-virtual-targeted-oncology-lri4rc1p0f13.html

User Image RallyRaider Posted - 1 week ago

$MEIP thats a lot of cash and a dollar is a dollar data pending q1/H1 2024 whats the science on this one?

User Image JohnGod Posted - 03/27/24

$MEIP I'm out with a decent loss. Gl to all. Looked so promising a while ago

User Image MJPTrades Posted - 03/26/24

$MEIP looks like management plans on continuing to spend capital and even possibly dilute to progress these phase 1 drugs that will not increase stock price or bring value to company in short or long term… makes no sense… literally makes 0 sense it’s terrible value… wonder what’s going on in terms of ME-344… if those results are bad then a second special dividend or buyout will occur but for now the other pipeline continue to burn precious cash

User Image Stock_Titan Posted - 03/26/24

$MEIP MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia https://www.stocktitan.net/news/MEIP/mei-pharma-reports-update-from-clinical-study-evaluating-oral-cdk9-menwt6pp1kn8.html

User Image telomerase Posted - 03/25/24

$KRON while we're watching $KRON go down, anyone have any thoughts on those other burning piles of cash, $ACHL and $MEIP?

User Image RollingDollar Posted - 03/25/24

$MEIP

User Image RollingDollar Posted - 1 month ago

$MEIP

User Image terrapin22 Posted - 1 month ago

$MEIP moving up

User Image RollingDollar Posted - 1 month ago

$MEIP

User Image RollingDollar Posted - 1 month ago

$MEIP

User Image RollingDollar Posted - 1 month ago

$MEIP

User Image Saitutti Posted - 1 month ago

$MEIP where's the bottom? Glad I sold two weeks ago but is it worth to jump back in... or is this stock the titanic

User Image MJPTrades Posted - 1 month ago

$MEIP officially liquidated the last of my position here today… it’s crazy how a massive value play like this can be absolutely destroyed by a stubborn management… the reality was that this investment should have returned anywhere from 40-70% in around half a year but instead Ive barely gotten out of this with only around a 10% loss (this is including the last special dividend)also Anson and Cable (specifically Moez Kassam and Taheer Dato)really disappointed me here with their campaign I really thought that they were competent vulture funds but in the end even they failed to make major change and from what ik many of their other major activist campaigns have essentially failed and brought little to no value or change… maybe they should just stick to illegally shorting trash cannabis stocks and use the classic warrant short strategy (like Hal Mintz aka Sabby Capital) to take advantage of micro nano small caps… overall another lesson learned that unless u have 9/10 figures ur powerless

User Image Trendrebel Posted - 1 month ago

$MEIP Interesting to hear their response. Im pretty sure, that Anson indicated that previous board was hopeless. I have a hard time to see any improvement now, where they put themselves around the table.

User Image Trendrebel Posted - 1 month ago

$MEIP Maybe its about time to contact IR and ask them, if we should feel delighted by the new board. Stock has lost almost 50% since they took over

User Image Nanu108 Posted - 1 month ago

$MEIP I'm in this today

User Image MJPTrades Posted - 02/27/24

$MEIP not enough volume here for me to get out even if I wanted to

User Image DonCorleone77 Posted - 02/20/24

$MEIP MEI Pharma files $100M mixed securities shelf

User Image Trendrebel Posted - 02/20/24

$MEIP Stock is more sick, than their patients !

User Image Jose1628 Posted - 2 months ago

$MEIP it’s crazy how voruciclib - oral cdk9 inhibitor phase 1 study showed good results with 40 patients, some with a type of blood cancer called AML and others with NHL, they tested the medicine called voruciclib at different doses. They found that at a dose of 200 mg, the medicine was safe and could be helpful in treating AML. The patients experienced some side effects like diarrhea and nausea, but overall, the medicine seemed promising in reducing the growth of cancer cells. Yet it goes down 😭

User Image epsguid Posted - 2 months ago

$MEIP reported a loss of $1.66, consensus was ($1.46) via @eWhispers #epsmiss http://eps.sh/d/meip

User Image Ninja_Tradez Posted - 2 months ago

📢 $MEIP - [MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights](<https://www.stocktitan.net/news/MEIP/mei-pharma-reports-second-quarter-fiscal-year-2024-results-and-3yziyiizgy4x.html>) | **sharesFloat**: 5M | **shortPercent**: 0.0497 | **marketCap**: 31M

Analyst Ratings
Stifel Hold Apr 12, 24
Stifel Hold Feb 14, 24
Stifel Hold Sep 27, 23
Brookline Capital Buy May 23, 23
Stifel Hold May 12, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anson Funds Management LP 10% Owner 10% Owner Sep 22 Buy 6.8525 48,060 329,331 864,188 09/25/23
Funicular Funds, LP 10% Owner 10% Owner Sep 22 Buy 6.8525 32,040 219,554 460,840 09/25/23
Anson Funds Management LP 10% Owner 10% Owner Sep 20 Buy 6.24 153,600 958,464 816,128 09/22/23
Funicular Funds, LP 10% Owner 10% Owner Sep 20 Buy 6.24 102,400 638,976 428,800 09/22/23